SAM
LYEL icon

Smartleaf Asset Management’s Lyell Immunopharma LYEL Stock Holding History

Smartleaf Asset Management’s Portfolio LYEL Stock Details LYEL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-13
Closed -$403 – 2977
2024
Q3 		$403 Buy
+13
New +$382 ﹤0.01% 2808

Other funds holding LYEL

MM
MWG Management Road Town, Tortola, British Virgin Islands $81.3M AUM 2.28% 1-Year Est. Return
OPL
Orland Properties Ltd Road Town, Tortola, British Virgin Islands $267M AUM 5.05% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DC
Decheng Capital Menlo Park, California $661M AUM 299.97% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FCMI
Foresite Capital Management IV Larkspur, California $237M AUM 107.53% 1-Year Est. Return
FCMV
Foresite Capital Management V Larkspur, California $271M AUM 309.87% 1-Year Est. Return
VP
venBio Partners San Francisco, California $281M AUM 261.03% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return

Smartleaf Asset Management's LYEL Position: Q4 2024 in Review

Smartleaf Asset Management sold out of Lyell Immunopharma (LYEL) in Q4 2024, closing a stake of 13 shares — an estimated $403 sold.

Smartleaf Asset Management first reported a position in LYEL in Q3 2024 and held it in 1 quarter. The position peaked at $403 in Q3 2024. 105 funds tracked by Wall St. Rank hold LYEL as of Q4 2024.

  • Smartleaf Asset Management reported no remaining Lyell Immunopharma position as of Q4 2024 after selling out during the quarter.
  • Smartleaf Asset Management sold 13 Lyell Immunopharma shares in Q4 2024, an estimated $403.
  • Smartleaf Asset Management first reported a position in Lyell Immunopharma in Q3 2024 and held it in 1 quarter.
  • Smartleaf Asset Management's Lyell Immunopharma position peaked at $403 in Q3 2024.
  • 105 funds tracked by Wall St. Rank held Lyell Immunopharma as of Q4 2024.

Based on Smartleaf Asset Management's 13F filing for Q4 2024, filed 5 Feb 2025.